- Facing pharmacy trends for the remainder of the year
- Cardinal Health invites independent pharmacy owners to ‘discover new horizons’ at RBC 2013
- Senate passes Drug Quality and Security Act
- Kathleen Sebelius cites pharmacists' importance as Rite Aid CEO introduces Obamacare resource program
- On the heels of Q3, Walgreens outlines shift in front-end strategy and pharmacy tailwinds looking forward
WHITEHOUSE STATION, N.J. — Drug maker Merck and drug industry services organization Parexel International will work together to develop biosimilars, the two said Wednesday.
Under the agreement, Parexel will give Merck BioVentures access to clinical and regulatory services for the development of biosimilars. Financial terms of the agreement were not disclosed.
“Parexel has extensive, industry-leading experience with biosimilar development, and we truly understand the scientific complexities and regulatory pathways involved,” Parexel chairman and CEO Josef von Rickenbach said. “We are committed to working with Merck BioVentures to assist in advancing its biosimilar portfolio in this rapidly developing market segment for the benefit of patients worldwide.”